Fibroblast growth factor‐21 protects against fibrosis in hypertensive heart disease

Citations Over TimeTop 15% of 2018 papers

Abstract

Abstract FGF21 is an endocrine factor that contributes to multiple pathophysiological processes, mainly via its action as a metabolic regulator and cardioprotective agent. Recent studies have shown increased circulating FGF21 levels in hypertensive patients and in mouse models of hypertension. However, the relevance of FGF21 in hypertensive heart disease has not been addressed. Hypertension was induced by treating 4‐month old WT and Fgf21 −/− mice with angiotensin II (AngII) for 1 week, resulting in a similar increase in blood pressure in both genotypes. Plasma FGF21 levels and expression in heart and liver were significantly increased in hypertensive WT mice relative to controls, an effect that was associated with increased expression levels of β‐klotho specifically in the heart. Fgf21 −/− mice developed a greater degree of hypertensive heart disease than WT mice, notably characterized by extensive cardiac dysfunction and fibrosis. In vitro and in vivo studies further showed that FGF21 exerted a marked protective effect against cardiac fibrosis. Finally, left ventricle biopsies from human hypertensive heart donors, especially those developing cardiomyopathy, showed a significant increase in FGF21expression compared with normotensive controls, a finding that was associated with significantly enhanced cardiac hypertrophy and fibrosis. We conclude that during hypertension, both systemic and cardiac‐produced FGF21 are induced and act on the heart, protecting it from hypertensive heart disease. Thus, FGF21 acts as key factor in the fibrogenesis associated with hypertensive heart disease. Copyright © 2018 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Related Papers

• → Irisin attenuates angiotensin II-induced cardiac fibrosis via Nrf2 mediated inhibition of ROS/ TGFβ1/Smad2/3 signaling axis(2019)78 cited
• → Angiotensin II increases collagen I expression via transforming growth factor-beta1 and extracellular signal-regulated kinase in cardiac fibroblasts(2009)111 cited
• → Smad7 inhibits angiotensin II-induced hypertensive cardiac remodelling(2013)69 cited
• → Angiotensin II up‐regulates the expression of scleraxis in cardiac myofibroblasts isolated from the site of myocardial infarction(2011)1 cited
• → Abstract P109: Angiotensin-(1-9) Reverses Cardiac Dysfunction in a Model of Angiotensin II-Induced Hypertensive Heart Disease by Acting as a Positive Inotrope(2015)